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Edited by Robert BaroukiAbstract The aim of this study was to evaluate the impact of
the lack of inducible NO synthase (iNOS) on body weight and
adipose tissue mass as well as on plasma leptin and adiponectin
in basal conditions and 6 h after lipopolysaccharide (LPS)
administration in mice. Body weight was not diﬀerent among
male, six-week-old wild-type (WT) and iNOS)/) animals.
However, the amount of epididymal white adipose tissue
(EWAT) in iNOS)/) mice was signiﬁcantly reduced
(P < 0:05). Circulating leptin and leptin mRNA in EWAT were
decreased in iNOS)/) mice (P < 0:05 and P < 0:01, respec-
tively). Plasma adiponectin and adiponectin mRNA were
unchanged. LPS administration increased plasma leptin in both
genotypes (P < 0:05). Neither genotype nor treatment changed
plasma adiponectin. In summary, iNOS)/) mice exhibited
normal body weight but reduced adipose mass accompanied by
hypoleptinemia. Leptin responsiveness to LPS in iNOS)/)
mutants is preserved, showing that the LPS-induced rise in
leptin is independent of the presence of functional iNOS. In
addition, iNOS deﬁciency or LPS does not inﬂuence expression
and circulating levels of adiponectin.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The increasing prevalence of obesity has drawn attention
to the need for intensiﬁed research directed at the elucidation
of the mechanisms regulating body weight and adipose tissue
mass [1]. Current evidence for the involvement of several
diﬀerent factors in energy balance regulation indicates that
body weight homeostasis is far more complex than initially
thought. The identiﬁcation of genes that cause obesity,
leanness or provide resistance to obesity development has
provided new clues in the understanding of body weight
control [2].
Nitric oxide (NO) is a gaseous signaling molecule, which
plays an important role in a wide variety of physiological* Corresponding author. Fax: +34-948-425652.
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doi:10.1016/j.febslet.2004.10.028functions, including inﬂammation, vascular tone and me-
tabolism [3]. NO is formed in an enzymatic reaction cata-
lyzed by three isoforms of NO synthase (NOS) cloned so
far. Endothelial NOS (eNOS) and neuronal NOS (nNOS)
are calcium dependent and constitutively expressed, while
inducible NOS (iNOS) is calcium independent and is syn-
thesized in response to a variety of stimuli [4]. Evidence of
NOS has been demonstrated in adipose tissue [5,6], indi-
cating that adipocytes are a potential source of NO pro-
duction. Furthermore, the involvement of NO in both rat
and human lipolysis has been reported [7–9]. Stimulation of
iNOS in skeletal muscle and white adipose tissue (WAT) has
been proposed as a link between obesity, inﬂammation and
insulin resistance [10]. In fact, increased iNOS expression in
adipocytes of genetic and dietary models of obesity has been
described [11]. Moreover, targeted disruption of iNOS has
been shown to protect against diet-induced insulin resistance
in muscle [11].
It is clearly established that adipose tissue secretes a wide
variety of biologically active molecules at the same time as
expressing receptors for numerous hormones and cytokines,
thus representing an extremely active endocrine organ [12].
In addition, adipose tissue plays an important role in the
obesity-related inﬂammatory process [13]. Leptin and
adiponectin are pleiotropic proteins expressed and secreted
mainly by adipose tissue, with a well-established participa-
tion in inﬂammatory processes [14,15]. Lipopolysaccharide
(LPS) is a component of the gram-negative bacterial cell
wall, which produces an inﬂammatory response and strongly
induces iNOS [16]. Leptin is increased already hours later
after LPS administration [17–19], and so far, the eﬀect of
LPS on adiponectin in mice is unknown. Since it is well
known that LPS induces NO production by stimulating the
synthesis of iNOS, we evaluated the eﬀect of the absence of
iNOS on the stimulation of leptin and adiponectin induced
by LPS.
The aim of the present study, therefore, was twofold. On the
one hand, to gain insight into the involvement of iNOS in body
weight regulation in mice by evaluating the lack of iNOS on
body weight and adipose tissue mass. On the other hand, to
study whether adiponectin is acutely regulated by LPS and to
evaluate the lack of iNOS on plasma leptin and adiponec-
tin concentrations in basal conditions and after LPS
administration.blished by Elsevier B.V. All rights reserved.
Table 1
Characteristics of iNOS= mice
Body weight (g) Epididymal WAT weight (g) Glucose (mg/dl) Insulin (ng/ml) Leptin (ng/ml) Adiponectin (lg/ml)
WT 20.2 0.6 0.215 0.043 96 10 2.3 1.8 0.67 0.17 8.36 2.07
iNOS= 20.2 1.3 0.114 0.012 164 37 0.9 0.4 0.23 0.04 9.46 1.62
Data are means S.E.M. from six-week-old male mice.
* P < 0:05 by two-tailed unpaired t test comparing values between wild type and iNOS=groups (n ¼ 6 per group).
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2.1. Animals and treatments
Wild-type (WT) and iNOS deﬁcient (iNOS=) mice [20] were bred
in the animal facilities of the University of Navarra. Mice were
maintained at an ambient temperature of 22 2 C on a 12:12 h light–
dark cycle (lights on at 08:00 h) under pathogen-free conditions and
given a standard laboratory diet (Rodent Toxicology Diet, B &
KUniversal Ltd., Hull, UK) and UV-irradiated tap water ad libitum.
Twenty-four six-week-old male mice (n ¼ 6 per group) were used in the
study. Between 10:00 and 10:30 a.m. LPS from Escherichia coli, sero-
type 055:B5 (SIGMA, Madrid, Spain) was administered intraperito-
neally at 5 mg/kg body weight to half of the mice (six WT and six
iNOS=), while the remaining animals were injected with vehicle
(PBS). All mice were fasted with free access to water during the ex-
periment. Six hours after LPS or vehicle administration, mice were
weighed and sacriﬁced by CO2 inhalation. Blood samples were col-
lected directly from the heart. Epididymal WAT (EWAT) was excised,
weighed, snap-frozen in liquid nitrogen and stored at )85 C until
extraction of RNA. Plasma was separated and stored at )85 C for
subsequent measurements. All experimental procedures conformed to
the European Guidelines for the Care and Use of Laboratory Animals
and the study was approved by the Ethical Committee for Animal
Experimentation of the University of Navarra.
2.2. Genotyping
To conﬁrm the iNOS genotype of the mice, genomic DNA was ex-
tracted from ear punches by using a DNeasy mini kit (QIAGEN Inc.,Fig. 1. Leptin and adiponectin mRNA expression in EWAT of WT
and iNOS= mice. Photographs show representative sets of PCR
products from individual mice. Bars represent meansS.E.M. of the
ratio between leptin and adiponectin to b-actin. The expression of
leptin and adiponectin in WT mice was assumed to be 1. ** P < 0:01
vs. WT mice by two-tailed unpaired t test; n ¼ 6 per group.Valencia, CA, USA). A minimal portion of the ear was cut into small
pieces and incubated with proteinase K solution. The obtained geno-
mic DNA was then eluted according to the manufacturer’s instruc-
tions. To identify the presence of the WT or the disrupted iNOS allele,
three primers were used. The primer 50-ACATGCAGAATGA-EWAT weight (g)
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Fig. 2. Scatter diagrams showing the positive correlation found be-
tween circulating concentrations of leptin and the weight of the epi-
didymal fat pads (A) and between concentrations of leptin and leptin
mRNA expression in EWAT (B) of WT (d) and iNOS= (s) mice.
Pearson’s correlation coeﬃcient and P values are indicated.
Fig. 3. iNOS mRNA expression in EWAT. WT or iNOS deﬁcient
(iNOS=) mice received an intraperitoneal injection of either LPS (5
mg/kg) or PBS. Photographs show representative sets of PCR products
from individual mice. Bars represent meansS.E.M. of the ratio be-
tween iNOS and b-actin. The expression of iNOS in WT mice was
assumed to be 1; n ¼ 6 per group.
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alleles and ampliﬁed a 108-bp fragment with the primer 50-TCAA-
CATCTCCTGGTGGAAC-30 speciﬁc for the genomic sequence and a
275-bp fragment with the primer 50-AATATGCGAAGTGG-
ACCTCG-30 complementary to a region of the neomycin resistance
insert speciﬁc to the disrupted iNOS allele [21]. The PCR was per-
formed as described elsewhere [21]. Two hundred nanograms of DNA
was used per reaction. The PCR products were then separated on 1.5%
agarose gel and visualized with ethidium bromide staining.
2.3. Plasma measurements
Blood samples were collected from the heart. Plasma glucose was
analyzed by an automated analyzer (Roche/Hitachi Modular P800),
with quantiﬁcation being based on enzymatic colorimetric reactions.
Plasma insulin was measured by means of an Ultra Sensitive Rat In-
sulin ELISA kit using mouse insulin as standard (Crystal Chem Inc.,
Chicago, IL, USA). Intra- and inter-assay coeﬃcients of variation
(CV) were 5.5% and 4.8%, respectively. Circulating concentrations of
leptin were measured by ELISA (Crystal Chem Inc.). Intra- and inter-
assay CV were 5.4% and 6.9%, respectively. Plasma adiponectin was
quantiﬁed by ELISA (B-Bridge International, Inc., San Jose, CA,
USA). Intra- and inter-assay CV were 4.2% and 5.9%, respectively. NO
was determined spectrophotometrically in plasma by its oxidation
products nitrite and nitrate (NOx) using a colorimetric assay (Cayman
Chemical Company, Ann Arbor, MI, USA). Nitrate present in sam-
ples is reduced to nitrite utilizing nitrate reductase. The addition of the
Griess Reagent converts nitrite into a deep purple azo compound.
Finally, the measurement of the absorbance at 540 nm accurately de-
termines NO2 concentration [22]. Concentrations were determined
compared with a standard curve of sodium nitrite. The detection limit
of the assay was 2.5 lM nitrite.
2.4. Semiquantitative reverse transcriptase-polymerase chain reaction
(RT-PCR)
Total RNA was extracted from 100 mg of EWAT samples by ho-
mogenization with an ULTRA-TURRAX T 25 basic (IKA Werke
GmbH, Staufen, Germany) using TRIzol reagent (Invitrogen, Carls-
bad, CA, USA) and the RNA concentration determined from absor-
bance at 260 nm. One lg of RNA was used to synthesize ﬁrst-strand
cDNA after treatment with DNase I (Roche, Basel, Switzerland). The
RT-PCRs were carried out as previously described [23]. Primers used
to amplify the cDNA of leptin (GenBank U22421) were 50-CCAG-
GATGACACCAAAACCC-30 and 50-TCCAACTGTTGAAGAA-
TGTCC-30, adiponectin (GenBank AF304466) 50-TGTTCCT-
CTTAATCCTGCCC-30 and 50-TCTCCTTTCTCTCCCTTCTC-30,iNOS (GenBank NM_010927) 50-TCATGGACCACCACACAGCC-
30 and 50-CGGATCTCTCTCCTCCTGGG-30, and b-actin (GenBank
X03672) 50-TCTACAATGAGCTGCGTGTG-30 and 50-GGTCAG-
GATCTTCATGAGGT-30. The pair of primers designed to analyze
iNOS mRNA expression ampliﬁed a 244-bp fragment of cDNA cod-
iﬁed within a region of the iNOS gene that was not included in the
target construct and, therefore, was absent in iNOS= mice. Primers
for leptin, adiponectin, and iNOS were designed using the Oligo 4.05
Primer Analysis Software (National Biosciences, Inc., Plymouth, MN,
USA). cDNA was ampliﬁed for 33 (leptin), 26 (adiponectin), 33
(iNOS) and 25 (b-actin) cycles, using the following parameters: 94 C
for 30 s, 56 C (leptin), 57 C (adiponectin), 58 C (iNOS) and 59 C
(b-actin) for 30 s and 72 C for 30 s, with a ﬁnal extension step at 72 C
for 7 min. Ampliﬁcations were linear under these conditions and were
carried out in a GeneAmp PCR System 2400 (Perkin–Elmer, Nor-
walk, CT, USA). All PCRs for each gene were performed at the same
time and with the same batch of Taq polymerase in order to reduce
variations in the eﬃciency of PCR. The ampliﬁed products were re-
solved in a 1.5% agarose gel with ethidium bromide. Levels of mRNA
were expressed as the ratio of signal intensity for each gene relative to
that of b-actin. The ratio of each gene/b-actin in the WT group was
assumed to be 1. The intensity of the PCR bands was determined by
densitometric analysis with the Gel Doc 1000 UV ﬂuorescent gel doc-
umentation system and Molecular Analyst 1.4.1 software for quanti-
tation of images (Bio-Rad, Hercules, CA, USA).
2.5. Statistical analysis
Data are presented as means S.E.M. Diﬀerences between WT and
iNOS= mice were analyzed by two-tailed unpaired t tests. The eﬀect
of LPS in both genotypes was analyzed by means of a two-way (ge-
notype and treatment) ANOVA. Correlations between two variables
were studied by Pearson’s correlation coeﬃcients. A P value lower
than 0.05 was considered statistically signiﬁcant. The calculations were
performed using the SPSS/Windows version 11.0.1 statistical package
(SPSS, Chicago, IL, USA).3. Results
3.1. iNOS= mice show reduced adipose mass and
hypoleptinemia
Body weight of mice lacking iNOS was not diﬀerent from
that of WT mice. However, iNOS= showed reduced adipose
tissue mass as evidenced by the smaller amount of EWAT,
which weighed less than EWAT of WT littermates (P < 0:05).
There were no changes in circulating concentrations of either
glucose or insulin. Plasma leptin concentrations were signiﬁ-
cantly reduced (P < 0:05) as expected after the reduced adi-
pose tissue mass. Despite having reduced amounts of body fat,
adiponectin concentrations remained unchanged in iNOS=
mice as compared to WT controls (Table 1).
3.2. Adipokines expression in iNOS= mice
Leptin expression was signiﬁcantly reduced in iNOS= mice
as compared to WT mice (P < 0:01). Similar to the ﬁnding in
plasma concentrations, no eﬀect of the lack of iNOS on adipo-
nectin expression in EWATwas observed (Fig. 1). According to
the circulating values, a signiﬁcant correlation between leptin
concentrations and theweight of epididymal fat padswas shown
(Fig. 2A). Likewise, a positive correlation between leptin
concentrations and leptin expression was observed (Fig. 2B).
3.3. Eﬀect of LPS on iNOS expression in WAT and plasma
NOx concentrations
As expected, iNOS mRNA expression was undetectable in
adipose tissue of iNOS= mice and was slightly increased by
LPS treatment in WT animals, although these diﬀerences felt
out of signiﬁcance (Fig. 3). However, LPS signiﬁcantly
Fig. 6. Eﬀect of LPS on plasma adiponectin concentrations. WT or
iNOS deﬁcient (iNOS=) mice received an intraperitoneal injection of
either LPS (5 mg/kg) or PBS. Six hours after administration, plasma
adiponectin was determined by ELISA. Values are means S.E.M.;
n ¼ 6 per group.
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iNOS= mice, showing that there is no induction of NO
production by LPS in iNOS deﬁcient mice (Fig. 4).
3.4. Eﬀect of LPS on adipokines plasma concentrations
Body weight was not diﬀerent among the groups receiving
PBS (Table 1) and LPS (WT: 20.0 0.4, iNOS=: 20.0 0.9;
NS). However, the iNOS= groups receiving either PBS
(Table 1) or LPS (WT: 0.193 0.020, iNOS=: 0.158 0.020;
P < 0:05 main eﬀect of genotype by ANOVA) showed a re-
duced adipose mass. Plasma leptin concentrations were sig-
niﬁcantly reduced in iNOS= mice (P ¼ 0:035) as mentioned
before, but were signiﬁcantly increased by LPS treatment
(P ¼ 0:018) in both genotypes, while there was no statistically
signiﬁcant interaction (P ¼ 0:091), meaning that the eﬀect of
LPS is independent of the presence of the mutation (Fig. 5).
Neither genotype nor LPS treatment changed plasma adipo-
nectin concentrations, showing that circulating adiponectin is
not aﬀected by either lack of iNOS or LPS administration
(Fig. 6).Fig. 4. Eﬀect of LPS on NO production. WT or iNOS deﬁcient
(iNOS=) mice received an intraperitoneal injection of either LPS
(5 mg/kg) or PBS. Six hours after administration, plasma nitrate and
nitrite concentrations were determined using the Griess reaction.
***P < 0:001 vs. other groups by ANOVA. Values are mean-
sS.E.M.; n ¼ 6 per group.
Fig. 5. Eﬀect of LPS on plasma leptin concentrations. WT or iNOS
deﬁcient (iNOS=) mice received an intraperitoneal injection of either
LPS (5 mg/kg) or PBS. Six hours after administration, plasma leptin
was determined by ELISA. *P < 0:05 main eﬀect of genotype and #
P < 0:05 main eﬀect of LPS by ANOVA. Values are meansS.E.M.;
n ¼ 6 per group.4. Discussion
The present study provided evidence that iNOS deﬁcient
mice show a signiﬁcant decrease in body fat. The weight of
epididymal fat pads in mutants was about half of that of WT,
while body growth was normal, as has been reported in other
mice models of leanness [24–26]. In iNOS= mutants, lean-
ness is not a consequence of decreased food intake. On the
contrary, these mice exhibit increased food intake compared to
WT controls [11]. Increased food intake is in agreement with
the reduced leptin concentrations found in our study. How-
ever, the hyperphagia described seems insuﬃcient to maintain
normal adiposity and due to some unknown mechanisms these
mice fail to accumulate fat under a normal diet. Therefore, it
may be suggested that iNOS= animals have an increased
energy expenditure. In this sense, it has been reported that NO
downregulates uncoupling protein-2 (UCP2) expression in
3T3F442A adipocytes [27], and UCPs are markedly involved
in energy expenditure regulation [2]. Although iNOS= mice
do not show a reduced systemic NO production, as evidenced
by NOx concentrations, the lack of iNOS may decrease NO
production in adipose tissue in an autocrine/paracrine fashion,
thereby increasing UCP2 expression and hence energy expen-
diture. On the other hand, a role of iNOS in the regulation of
sympathetically mediated blood ﬂow in brown adipose tissue
has also been described [6,28], arguing against an increased
energy expenditure in this tissue in iNOS= mice. Further-
more, eNOS deﬁcient mice show reduced energy expenditure
and increased body weight [29], suggesting that NO involve-
ment in the regulation of energy expenditure is complex and
may exhibit NOS-speciﬁc diﬀerences. Increased energy ex-
penditure associated to increased locomotor activity can be
excluded given the fact that NO has been reported to induce
locomotor activity in mice [30] and eNOS deﬁcient mice show
normal locomotor activity [29]. Another possibility explaining
the observed reduced adiposity in iNOS= mice is related to
an increased lipolytic activity. This reasoning is supported by
the observation that blockade of NO production with an in-
hibitor of NOS increases the lipolytic rate in humans, indi-
cating an inhibitory eﬀect of NO on lipolysis [8]. Reduced
adipose mass of iNOS= mice might also be due to impaired
adipogenesis. In this sense, NO has been shown to promote
diﬀerentiation of rat white preadipocytes in culture [31]. Fur-
J. Gomez-Ambrosi et al. / FEBS Letters 577 (2004) 351–356 355ther analyses are required to unravel the underlying causes of
reduced adipose mass in iNOS deﬁcient mice.
Hypoleptinemia of iNOS= mice is accompanied by re-
duced leptin expression in EWAT. Leptin has been shown to
induce the release of NO [9,32,33], but to our knowledge, no
data regarding the eﬀect of NO on leptin expression and se-
cretion have been reported so far. The reduced expression and
circulating concentrations of leptin found in our study may
well reﬂect the reduced adipose mass [34] as evidenced by the
positive correlations found, although a direct eﬀect of iNOS
derived NO on leptin expression cannot be discarded.
Plasma concentrations of glucose and insulin were not sig-
niﬁcantly modiﬁed by the lack of iNOS. iNOS= mice have
been shown to exhibit normal glycemia and insulinemia under
a chow diet, while being resistant to developing hyperinsuli-
nemia under a high-fat diet as a consequence of their protec-
tion against insulin resistance in skeletal muscle [11].
Circulating concentrations of adiponectin were unaltered in
iNOS= mice, which is in agreement with the absence of
signiﬁcant changes in the concentrations of glucose and insu-
lin, given the insulin-sensitizing nature of this adipokine [35].
On the other hand, adiponectin increases NO production in
human and bovine aortic endothelial cells [36–38], but the ef-
fect of NO on adiponectin is unknown so far. Our data show
that adiponectin expression in EWAT and plasma concentra-
tions is not regulated by iNOS-derived NO as evidenced by the
studies performed in iNOS= and WT mice receiving LPS.
RT-PCR experiments studying iNOS expression in adipose
tissue conﬁrmed the presence of iNOS mRNA in adipose tissue
of WT mice and the lack of expression in iNOS= mice. Al-
though iNOS is a protein considered to be inducible, some
degree of basal expression can be detected in white adipose
tissue under physiological circumstances by both RT-PCR
[11,16] and Western blot [5,39]. iNOS mRNA was slightly
increased by LPS treatment in WT animals, although these
diﬀerences felt out of signiﬁcance. Previous studies have shown
that LPS administration induces a strong increase in iNOS
mRNA expression in EWAT [16,40]. However, in those ex-
periments, which were performed in rats receiving a higher
dose of LPS (15–20 mg/kg), the peak of induction of iNOS
mRNA was observed 4 h after administration and was unde-
tectable after 8 h [16]. The apparent lack of induction found in
our study may relate to several factors, including the animal
model used and the time point (6 h) at which iNOS mRNA
expression was measured, since the peak eﬀect of LPS on iNOS
mRNA expression may be missed. However, LPS signiﬁcantly
increased plasma NOx of WT mice, with no eﬀect on iNOS
=
mice. This indicates that the induction of iNOS by LPS and,
therefore, the increase in NO production was notable in WT
mice and totally absent in iNOS deﬁcient mice.
The well described increase in leptin concentrations after
LPS administration could be mediated by corticoids [19], IL-
1b [41], TNFa [42], or neurally mediated [43]. This eﬀect takes
place apparently by NO-independent mechanisms, because the
eﬀect is equally observed after blocking NO production with
L-NAME [19]. To explore whether LPS was able to induce
leptin in the absence of functional iNOS, the eﬀect of intra-
peritoneal LPS in iNOS deﬁcient mice was tested. Despite
having reduced leptinemia, LPS increased plasma leptin con-
centrations in iNOS deﬁcient mice to a similar extent than in
normal mice. This ﬁnding conﬁrms the independence of NO in
endotoxemia-derived hyperleptinemia, showing that the LPS-induced rise in leptin circulating concentrations is independent
of the presence of functional iNOS.
Adiponectin is an adipokine with anti-inﬂammatory prop-
erties, in addition to its well-known insulin sensitizing eﬀects
[15,44]. Anti-inﬂammatory actions of adiponectin are medi-
ated in part by suppression of NFjB signaling and ERK1/2
activity [45]. Moreover, adiponectin suppresses LPS-induced
TNFa mRNA expression in macrophages [46]. The present
study demonstrates that LPS does not change plasma con-
centrations of adiponectin with independence of the presence
of functional iNOS. Experiments in humans have shown that
adiponectin concentrations are reduced during a resting and
fasting state, and that this reduction is slightly reversed by
endotoxin [47]. However, the eﬀect was very small and diﬀer-
ences between species in the regulation of adiponectin ex-
pression may explain the diﬀerent response observed, given the
fact that adiponectin in mice is not aﬀected by fasting [48]. In
addition, it has been recently described that adiponectin is not
acutely regulated by endotoxemia in pigs [49]. Our data sug-
gest that, at least in mice, adiponectin is not involved in the
acute inﬂammatory response to LPS.
In summary, mice lacking iNOS exhibit a normal body
weight but reduced adipose mass accompanied by hypolep-
tinemia. The deﬁciency of iNOS does not aﬀect adiponectin
expression and circulating concentrations. In addition, the
LPS-induced increase in leptin concentrations is independent
of iNOS and LPS does not inﬂuence circulating concentrations
of adiponectin. Our data support the involvement of NO and
iNOS in adipose mass regulation.
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